mRNA cancer vaccine cuts melanoma recurrence in landmark late-stage trial

US drugmakers Merck and Moderna announced that a personalised mRNA cancer vaccine successfully reduced melanoma recurrence in a large, late-stage clinical trial. It marks the first time an mRNA-based drug has shown positive results in a phase-three oncology trial. Experts described the outcome as a "breakthrough."